

## CLINICAL REVIEW

## Tobacco Use Treatment in Primary Care Patients with Psychiatric Illness

Joseph M. Cerimele, MD, Abigail C. Halperin, MD, MPH, and Andrew J. Saxon, MD

**The prevalence of smoking is higher in patients with psychiatric illness compared with the general population. Smoking causes chronic illnesses, which lead to premature mortality in those with psychiatric illness, is associated with greater burden of psychiatric symptoms, and contributes to the social isolation experienced by individuals with psychiatric disorders. Most patients with a psychiatric illness present initially to primary care rather than specialty care settings, and some patients receive care exclusively in the primary care setting. Therefore, family physicians and other primary care clinicians have an important role in the recognition and treatment of tobacco use disorders in patients with psychiatric illnesses. In this article we review common myths associated with smoking and psychiatric illness, techniques for implementing evidence-based tobacco use treatments, the evidence base for tobacco use treatment for patients with specific psychiatric diagnoses, and factors to consider when treating tobacco use disorders in patients with psychiatric illness. (J Am Board Fam Med 2014;27:399–410.)**

**Keywords:** Mental Disorders, Tobacco Use Cessation

Tobacco use is common among patients with psychiatric disorders.<sup>1</sup> While smoking prevalence among the general adult population is 20%, almost one half of patients with bipolar disorder and two thirds of patients with schizophrenia seen in clinical settings smoke,<sup>2</sup> and the decline in smoking prevalence in the United States that has occurred among the general population has not occurred in the population with psychiatric illness.<sup>3</sup> Furthermore, tobacco use disorders occur in one third to one half of patients with common psychiatric illnesses such as major depressive disorder, posttraumatic stress

disorder (PTSD), or 1 of 3 anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder).<sup>4</sup> Smokers with psychiatric illness also consume more cigarettes per day compared with smokers without psychiatric illness.<sup>5</sup> Consequently, between 31% to 44% of all cigarettes in the United States are smoked by individuals with psychiatric illnesses, which occur in about 20% of the population annually.<sup>4,6</sup>

Chronic diseases caused by smoking, such as hypertension and chronic obstructive pulmonary disease, are more common among patients with psychiatric illness compared with those without psychiatric disorders.<sup>7,8</sup> In addition, such chronic illnesses generally occur earlier in life in these patients, leading to a greater degree of illness-related disability and impairment.<sup>9</sup> Unfortunately, the life expectancy of people with psychiatric illnesses such as schizophrenia and bipolar disorder is approximately 10 to 20 years less than the general population, largely because of premature deaths from smoking-related illnesses.<sup>10–12</sup>

The disparity in tobacco use between individuals with and without psychiatric illness is present in primary care settings as well. In one study, primary care patients with psychiatric disorders were twice as likely to be current smokers compared with those

This article was externally peer reviewed.

Submitted 6 September 2013; revised 13 January 2014; accepted 21 January 2014.

From the Department of Psychiatry and Behavioral Sciences (JMC), the Department of Family Medicine (ACH), School of Medicine, and the Department of Health Services, School of Public Health (ACH), University of Washington, Seattle; and the Veteran's Affairs Puget Sound Health Care System, Seattle, WA (AJS).

Funding: JMC is supported by a grant from the National Institute of Mental Health (T-32 MH020021-16).

Conflict of interest: AJS has served on the scientific advisory board for Alkermes, Inc., and as a speaker for ReckittBenckiser, Inc.

Corresponding author: Joseph M. Cerimele, MD, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 1959 NE Pacific St., Box 356560, Seattle, WA 98195 (E-mail: cerimele@uw.edu).

without psychiatric illness (41.1% vs 19.5%;  $P = .002$ ).<sup>13</sup> Family physicians are well positioned to initiate tobacco use treatment for patients with psychiatric illness since most of these patients initially present in primary care settings.<sup>14</sup> Furthermore, national efforts by the Centers for Disease Control and Prevention encouraging smokers to ask their doctors about smoking will likely lead to more patients initiating discussions with primary care doctors about their cigarette use.<sup>15</sup> Many patients with common psychiatric conditions such as depression are treated by primary care physicians without referral to specialty mental health care providers, and patients who smoke generally prefer receiving tobacco use treatment in their primary care clinic.<sup>16</sup> Based on patients' service utilization and preferences, the primary care setting may be the only opportunity many patients with psychiatric illness have to receive tobacco use treatment.

Despite the known negative consequences of smoking, clinicians often feel uncomfortable addressing tobacco use with patients in general, and this is particularly true when patients have psychiatric diagnoses.<sup>12</sup> Primary care physicians' efforts to treat tobacco use in patients with psychiatric illness can be enhanced by dispelling common myths and misperceptions about why patients with psychiatric disorders smoke and by improving knowledge of evidence-based treatment options.

This article is a narrative review of the treatment of tobacco use disorders in primary care patients with psychiatric illnesses. We identified relevant articles for this review by searching PubMed, the Cochrane database, and GoogleScholar. We also searched the reference lists of key articles for additional relevant reports. We will not cover the research examining tobacco use treatment in patients with substance use disorders because of our intent to focus on other psychiatric illnesses such as depression and bipolar disorder.

### Myths about Psychiatric Illness and Smoking

Prochaska<sup>17</sup> described 5 myths associated with clinicians' reluctance to provide tobacco use treatment to patients with psychiatric illness. First is that patients with psychiatric illness smoke for "necessary self-medication."<sup>17</sup> Six studies prospectively measured associations between smoking and psychiatric symptom severity over at least 6 months in patients with bipolar disorder or schizophrenia

who smoked compared with patients who did not smoke.<sup>18</sup> Five studies showed that those who smoked cigarettes experienced higher symptom burden, as evidenced by more frequent suicidal thoughts,<sup>19</sup> higher severity of negative symptoms of schizophrenia<sup>20</sup> and bipolar disorder,<sup>21</sup> higher rates of alcohol and cannabis use,<sup>21,22</sup> and a greater number of days spent in a psychiatric hospital.<sup>21</sup> These findings are consistent with evidence showing that use of other addictive substances, such as alcohol, is associated with higher psychiatric symptom burden, greater treatment resistance, and greater risk of relapse in patients with co-occurring psychiatric illness substance use.<sup>23</sup>

The second myth is that "people with mental illness are not interested in quitting smoking." Smokers with psychiatric illness are just as likely as smokers without psychiatric illness to express interest in quitting smoking.<sup>17</sup> For example, among more than 500 current smokers with bipolar disorder, approximately three-quarters reported wanting to quit smoking, consistent with the rate among the general population.<sup>24</sup> In addition, patients with bipolar disorder had a median of 4 prior quit attempts, suggesting that individuals remained interested in quitting despite prior unsuccessful attempts.

The third myth listed by Prochaska<sup>17</sup> is that "mentally ill people cannot quit smoking." Several systematic reviews and meta-analyses<sup>1,25–29</sup> have shown that, when treated with appropriate tobacco use treatments, patients with psychiatric illness can achieve abstinence from cigarettes at a rate only slightly lower than patients without psychiatric illness.<sup>5</sup>

The fourth myth describes the belief that "quitting smoking interferes with recovery from mental illness."<sup>17</sup> Research suggests that smoking cessation does not interfere with psychiatric illness treatment and may actually improve treatment outcomes.<sup>17,28</sup> For example, McFall et al<sup>30</sup> showed that initiating tobacco use treatment concurrently with PTSD treatments was associated with greater prolonged abstinence and no worsening in symptoms of PTSD. In addition, smokers with baseline anxiety or depressive disorder who continued smoking were more likely to have major depression (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.003–3.85) or a substance use disorder (OR, 2.51; 95% CI, 1.13–5.56) at 3-year follow-up compared with individuals who quit smoking.<sup>31</sup>

The final myth is that smoking cessation is a low priority for patients with psychiatric symptoms. Clinicians treating patients with psychiatric illness often encounter competing demands such as co-occurring general medical, substance use, and psychosocial problems. However, for patients with psychiatric illness, smoking causes chronic illnesses and premature mortality,<sup>11</sup> contributes to social isolation and financial stress,<sup>5</sup> and is associated with poor nutrition<sup>32</sup> and higher psychiatric symptom burden.<sup>18</sup> As such, clinicians should consider smoking and its consequences as high-priority clinical problems.

### General Treatment Principles

The US Public Health Service (USPHS) clinical practice guideline by Fiore and Baker<sup>33</sup> comprehensively describes the evidence and proven techniques for clinical management of tobacco use disorders. Two subsequent review articles describe updates in evidence-based clinical practice.<sup>34,35</sup> Much of the discussion below draws from these key resources. The principles of smoking cessation apply equally to the treatment of smokers with and without psychiatric illness. We briefly review 5 categories of tobacco use treatment principles and practice: addressing nicotine withdrawal, case identification and counseling, enhancing motivation to quit, medications for smoking cessation, and telephone quit lines.

#### Nicotine Withdrawal

Abrupt cessation or reduction in nicotine consumption results in a withdrawal syndrome characterized by irritability, sleep problems, dysphoria, lowered frustration tolerance, impaired concentration, restlessness, increased appetite, lowered heart rate, and cigarette cravings.<sup>36</sup> These symptoms may last up to 4 weeks, with most patients experiencing a higher intensity of symptoms during the first week of abstinence.<sup>37</sup> Primary care physicians can help patients understand the nicotine withdrawal syndrome and offer treatment with nicotine replacement therapy, other approved cessation medications, and/or behavioral coping strategies to alleviate the discomfort caused by nicotine withdrawal.<sup>37</sup>

Nicotine withdrawal symptoms can mimic symptoms of patients' primary psychiatric illnesses, such as major depression and generalized anxiety

disorder.<sup>35</sup> Because nicotine withdrawal symptoms are lessened with exposure to nicotine (ie, when smoking a cigarette), many patients and clinicians believe that cigarettes treat psychiatric symptoms when in fact resuming smoking is only lessening the symptoms of nicotine withdrawal.<sup>12,36</sup> In addition, patients with psychiatric illnesses may experience more severe nicotine withdrawal symptoms. Since greater severity of nicotine withdrawal symptoms is associated with smoking relapse, it is important to help patients accurately recognize symptoms of nicotine withdrawal and to offer treatments for it.<sup>33,35,38,39</sup>

#### Case Identification and Counseling

Almost three quarters of smokers attend at least one primary care appointment per year.<sup>34</sup> Enhancing recognition of smokers in primary care is important so that effective treatments can be initiated for patients who are motivated to quit smoking and strategies to increase motivation can be used for patients who are not ready to quit.<sup>34</sup> The 2008 USPHS clinical practice guideline<sup>33</sup> recommends using the 5 As technique for case identification and treatment (Ask about tobacco use; Advise to quit; Assess willingness to make a quit attempt; Assist in a quit attempt; Arrange follow-up). One way to incorporate the 5 As into clinical practice is to ask each patient about smoking while measuring vital signs and record smoking status as a vital sign.<sup>40</sup> The primary care clinician then will be able to implement the remaining 4 As for those patients answering "yes" to the question about current tobacco use.

A large effectiveness trial involving 2325 patients in 9 primary care clinics showed that clinicians in routine practice tended to use only the first 2 As (Ask and Advise) more often than all 5 As.<sup>41</sup> However, patients receiving treatment using the 5 As were more likely to quit smoking (OR, 1.82; 95% CI, 1.16–2.86 for counseling and OR, 2.23; 95% CI, 1.56–3.2 for pharmacotherapy), arguing for the importance of using all 5 components.

#### Enhancing Motivation to Quit

Approximately 30% of smokers report not being interested in quitting smoking,<sup>42</sup> and patients who say they want to stop smoking often have mixed feelings about making a quit attempt.<sup>34</sup> Enhancing motivation to quit is thus a critical part of tobacco use treatment and can be done

using motivational interviewing (MI), an evidence-based approach used to address patients' ambivalence about behavior change. Expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy are key strategies in MI.<sup>33</sup> MI has been shown to be effective in treating tobacco dependence both alone and in combination with medication. A Cochrane review<sup>43</sup> showed that MI significantly increased abstinence from smoking at 6 months compared with usual care or brief advice (relative risk [RR], 1.27; 95% CI, 1.14–1.42).

In addition to MI, the 2008 USPHS clinical practice guideline<sup>33</sup> recommends using the 5 Rs technique to enhance motivation, whereby patients are asked to identify the personal **R**elevance of quitting smoking, the short- and long-term **R**isks of continued smoking, the **R**ewards of quitting smoking, and the anticipated **R**oadblocks to quitting. The clinician should **R**epeat these techniques each time the smoker is seen in the clinic until he or she has successfully quit.<sup>33</sup>

### **Smoking Cessation Medications**

All patients should be encouraged to use counseling and pharmacotherapy since the combination is more effective than either intervention alone.<sup>33</sup> Seven first-line pharmacological agents have been approved by the Food and Drug Administration (FDA) for tobacco use treatment, including 2 non-nicotine medications (bupropion and varenicline) and 5 forms of nicotine replacement (patch, gum, lozenge, nasal spray, and inhaler).<sup>33–35</sup> Two second-line agents (clonidine and nortriptyline) have evidence supporting their effectiveness in tobacco use treatment but do not have FDA indications.<sup>33</sup> Patients' odds of achieving abstinence are approximately doubled when using any of these 7 medications during a quit attempt.<sup>33–35</sup> Adding counseling to medication treatment increases abstinence rates by approximately 50% over medication treatment alone.<sup>33</sup>

Three preparations of nicotine replacement (patch, gum, lozenge) are sold over the counter, and 2 preparations are prescription only (inhaler and nasal spray).<sup>35</sup> Patients using any of the nicotine replacement products, including over-the-counter products, should be counseled on appropriate use since many misperceptions about nicotine replacement exist. The transdermal patch delivers nicotine slowly over 24 hours and must be replaced daily.

Heavy smokers may require more than one patch to achieve relief from nicotine withdrawal and often benefit from combining the patch with a faster-onset and shorter-duration form of nicotine replacement (the nicotine gum, lozenge, inhaler, or nasal spray), which are generally dosed several times daily. Combination treatment with the nicotine patch plus nicotine lozenge, where the patch is applied daily and the lozenge is used as needed, resulted in the highest abstinence rates compared with 4 other treatment options in 2 trials.<sup>44,45</sup>

In a randomized controlled trial that largely excluded individuals with psychiatric illness, the combination of varenicline and bupropion was superior to varenicline alone in producing prolonged abstinence rates at 12 and 26 weeks but not at 52 weeks.<sup>46</sup> A recent analysis of 17 clinical trials involving more than 8000 patients showed that use of varenicline was not associated with adverse neuropsychiatric events,<sup>47</sup> although a black box warning from 2009 advises clinicians to assess for adverse neuropsychiatric events in patients taking varenicline. Additional information on each of the 7 FDA-approved medications is shown in Table 1.

### **Tobacco Quitlines**

Telephone quitlines provide effective treatment for tobacco dependence. Current state quitlines (1-800-QUIT-NOW) connect individuals with counselors who deliver phone-based interventions and assist callers with finding local clinicians who can provide tobacco use treatment.<sup>48</sup> In addition, many states offer fax referral systems for clinicians to refer patients directly to a quitline, and some states also offer nicotine replacement therapy. A large trial of 3282 smokers showed that quitlines delivering a protocol-based smoking cessation intervention of up to 7 phone sessions approximately doubled quit rates (6-month abstinence, 11.7% vs 5.2%) compared with quitlines delivering self-help materials and information about smoking.<sup>49</sup> One study showed that quitline callers with major depression could achieve abstinence at 2 months, although a lower percentage of callers with depression achieved 2-month abstinence compared with callers without depression (18.5% vs 28.4%).<sup>50</sup>



Table 1. Food and Drug Administration–Approved Medications for Smoking Cessation

Product	NRT Formulations						Varenicline
	Gum	Lozenge	Transdermal Patch	Nasal Spray	Oral Inhaler	Bupropion SR	
Nicorette,* generic	Nicorette,* generic	Nicorette lozenge*	NicoDerm CQ,* generic	Nicotrol NS†	Nicotrol inhaler†	Zyban,* generic	Chantix†
OTC	OTC	Nicorette mini lozenge*	OTC (NicoDerm CQ, generic)	Rx	Rx	Rx	Rx
2 or 4 mg	Generic	Generic	Rx (generic)	Metered spray	10-mg Cartridge	150-mg Sustained-release tablet	0.5- or 1-mg Tablet
	OTC	OTC	7, 14, or 21 mg	0.5 mg nicotine in 50 µL aqueous nicotine solution	Delivers 4 mg inhaled nicotine vapor		
	2 or 4 mg		24-Hour release				
Precautions	Precautions for all NRT formulations ■ Recent (≤2 weeks) myocardial infarction ■ Serious underlying arrhythmias ■ Serious or worsening angina pectoris ■ Pregnancy* (category D) and breastfeeding ■ Adolescents (<18 years old) Precautions specific to certain NRT formulations ■ Gum: Temporomandibular joint disease ■ Nasal spray: Underlying chronic nasal disorders (rhinitis, nasal polyps, sinusitis); severe reactive airway disease ■ Oral inhaler: Bronchospastic disease					■ Medications or medical conditions known to lower the seizure threshold ■ Severe hepatic cirrhosis ■ Pregnancy* (category C) and breastfeeding ■ Adolescents (<18 years old) <b>Warning:</b> ■ Black-box warning for neuropsychiatric symptoms\$	■ Severe renal impairment (dosage adjustment is necessary) ■ Pregnancy* (category C) and breastfeeding ■ Adolescents (<18 years old) <b>Warning:</b> ■ Black-box warning for neuropsychiatric symptoms+

Continued

Table 1. Continued

NRT Formulations					
	Gum	Lozenge	Transdermal Patch	Nasal Spray	Oral Inhaler
Dosing	<p>First cigarette <math>\leq 30</math> minutes after waking: 4 mg</p> <p>First cigarette <math>&gt; 30</math> minutes after waking: 2 mg</p> <p>Weeks 1 to 6: 1 piece q 1 to 2 hours</p> <p>Weeks 7 to 9: 1 piece q 2 to 4 hours</p> <p>Weeks 10 to 12: 1 piece q 4 to 8 hours</p> <p>Maximum, 24 pieces/day</p> <p>Chew each piece slowly</p> <p>Park between cheek and gum when peppery or tingling sensation occurs</p> <p>Resume chewing when tingle fades</p> <p>Repeat chew/park steps until most of the nicotine is gone (generally 30 minutes)</p> <p>Park in different areas of mouth</p> <p>No food or beverages 15 minutes before or during use</p> <p>Duration: up to 12 weeks</p>	<p>First cigarette <math>\leq 30</math> minutes after waking: 4 mg</p> <p>First cigarette <math>&gt; 30</math> minutes after waking: 2 mg</p> <p>Weeks 1 to 6: 1 lozenge q 1 to 2 hours</p> <p>Weeks 7 to 9: 1 lozenge q 2 to 4 hours</p> <p>Weeks 10 to 12: 1 lozenge q 4 to 8 hours</p> <p>Maximum, 20 lozenges/day</p> <p>Allow to dissolve slowly (20–30 minutes for standard; 10 minutes for mini)</p> <p>Nicotine release may cause a warm, tingling sensation</p> <p>Do not chew or swallow</p> <p>Occasionally rotate to different areas of the mouth</p> <p>No food or beverages 15 minutes before or during use</p> <p>Duration: up to 12 weeks</p>	<p><math>&gt; 10</math> Cigarettes/day: 21 mg/day <math>\times</math> 4 weeks (generic)</p> <p>6 weeks (NicoDerm CQ)</p> <p>14 mg/day <math>\times</math> 2 weeks</p> <p>7 mg/day <math>\times</math> 2 weeks</p> <p><math>\leq 10</math> Cigarettes/day: 14 mg/day <math>\times</math> 2 weeks</p> <p>7 mg/day <math>\times</math> 2 weeks</p> <p>Patient may wear patch for 16 hours if experiencing sleep disturbances (remove at bedtime)</p> <p>Duration: 8 to 10 weeks</p>	<p>1 to 2 Doses/hour (8–40 doses/day)</p> <p>One dose = 2 sprays (one in each nostril); each spray delivers 0.5 mg of nicotine to the nasal mucosa</p> <p>Maximum, 5 doses/hour or 40 doses/day</p> <p>For best results, initially use at least 8 doses/day</p> <p>Do not sniffl, swallow, or inhale through the nose as the spray is being administered</p> <p>Duration: 3 to 6 months</p>	<p>6 to 16 Cartridges/day; individualize dosing; initially use 1 cartridge q 1 to 2 hours</p> <p>Best effects with continuous puffing for 20 minutes</p> <p>Initially use at least 6 cartridges/day</p> <p>Nicotine in cartridge is depleted after 20 minutes of active puffing</p> <p>Inhale into back of throat or puff in short breaths</p> <p>Do NOT inhale into the lungs (like a cigarette) but “puff” as if lighting a pipe</p> <p>Open cartridge retains potency for 24 hours</p> <p>No food or beverages 15 minutes before or during use</p> <p>Duration: 3 to 6 months</p>
Adverse Effects	<p>Mouth/jaw soreness</p> <p>Hiccups</p> <p>Dyspepsia</p> <p>Hypersalivation</p> <p>Effects associated with incorrect chewing technique:</p> <p>-Lightheadedness</p> <p>-Nausea/vomiting</p> <p>-Throat and mouth irritation</p>	<p>Nausea</p> <p>Hiccups</p> <p>Cough</p> <p>Heartburn</p> <p>Headache</p> <p>Flatulence</p> <p>Insomnia</p>	<p>Local skin reactions (erythema, pruritus, burning)</p> <p>Headache</p> <p>Sleep disturbances (insomnia, abnormal/vivid dreams); associated with nocturnal nicotine absorption</p>	<p>Nasal and/or throat irritation (hot, peppery, or burning sensation)</p> <p>Rhinitis</p> <p>Tearing</p> <p>Sneezing</p> <p>Cough</p> <p>Headache</p>	<p>Mouth and/or throat irritation</p> <p>Cough</p> <p>Headache</p> <p>Rhinitis</p> <p>Dyspepsia</p> <p>Hiccups</p> <p>Insomnia</p> <p>Dry mouth</p> <p>Nervousness/difficulty concentrating</p> <p>Rash</p> <p>Constipation</p> <p>Seizures (risk is 0.1%)</p> <p>Neuropsychiatric symptoms (rare; see Precautions)</p>
					<p>Days 1 to 3: 0.5 mg po q AM</p> <p>Days 4 to 7: 0.5 mg po bid</p> <p>Weeks 2 to 12: 1 mg po bid</p> <p>Begin therapy 1 week before quit date; alternatively, the patient can begin therapy and then quit smoking between days 8–35 of treatment</p> <p>Take dose after eating and with a full glass of water</p> <p>Dose tapering is not necessary</p> <p>Dosing adjustment is necessary for patients with severe renal impairment</p> <p>Duration: 12 weeks; an additional 12-week course may be used in selected patients</p> <p>Nausea</p> <p>Sleep disturbances (insomnia, abnormal/vivid dreams)</p> <p>Constipation</p> <p>Flatulence</p> <p>Vomiting</p> <p>Neuropsychiatric symptoms (rare; see Precautions)</p>

Continued

**Table 1. Continued**

NRT Formulations					
	Gum	Lozenge	Transdermal Patch	Nasal Spray	Oral Inhaler
Advantages	<ul style="list-style-type: none"> <li>■ Might satisfy oral cravings</li> <li>■ Might delay weight gain</li> <li>■ Patients can titrate therapy to manage withdrawal symptoms</li> <li>■ Variety of flavors are available</li> </ul>	<ul style="list-style-type: none"> <li>■ Might satisfy oral cravings</li> <li>■ Might delay weight gain</li> <li>■ Easy to use and conceal</li> <li>■ Patients can titrate therapy to manage withdrawal symptoms</li> <li>■ Variety of flavors are available</li> </ul>	<ul style="list-style-type: none"> <li>■ Provides consistent nicotine levels over 24 hours</li> <li>■ Easy to use and conceal</li> <li>■ Once daily dosing associated with fewer compliance problems</li> <li>■ Approved by the FDA for use in combination with bupropion SR</li> </ul>	<ul style="list-style-type: none"> <li>■ Patients can titrate therapy to rapidly manage withdrawal symptoms</li> </ul>	<ul style="list-style-type: none"> <li>■ Patients can titrate therapy to manage withdrawal symptoms</li> <li>■ Mimics hand-to-mouth ritual of smoking (could also be perceived as a disadvantage)</li> </ul>
Disadvantages	<ul style="list-style-type: none"> <li>■ Need for frequent dosing can compromise compliance</li> <li>■ Might be problematic for patients with significant dental work</li> <li>■ Patients must use proper chewing technique to minimize adverse effects</li> <li>■ Gum chewing may not be socially acceptable</li> </ul>	<ul style="list-style-type: none"> <li>■ Need for frequent dosing can compromise compliance</li> <li>■ Gastrointestinal side effects (nausea, hiccups, heartburn) might be bothersome</li> </ul>	<ul style="list-style-type: none"> <li>■ Patients cannot titrate the dose to acutely manage withdrawal symptoms</li> <li>■ Allergic reactions to adhesive might occur</li> <li>■ Patients with dermatologic conditions should not use the patch</li> </ul>	<ul style="list-style-type: none"> <li>■ Need for frequent dosing can compromise compliance</li> <li>■ Nasal/throat irritation may be bothersome</li> <li>■ Patients must wait 5 minutes before driving or operating heavy machinery</li> <li>■ Patients with chronic nasal disorders or severe reactive airway disease should not use the spray</li> </ul>	<ul style="list-style-type: none"> <li>■ Need for frequent dosing can compromise compliance</li> <li>■ Initial throat or mouth irritation can be bothersome</li> <li>■ Cartridges should not be stored in very warm conditions or used in very cold conditions</li> <li>■ Patients with underlying bronchospastic disease must use with caution</li> </ul>
Cost/day <sup>ll</sup>	2 or 4 mg: \$1.90–\$5.48 (9 pieces)	2 or 4 mg: \$3.05–\$4.10 (9 pieces)	\$1.52–\$3.40 (1 patch)	\$4.32 (8 doses)	\$7.74 (6 cartridges)
				\$2.54–\$6.22 (2 tablets)	\$6.54 (2 tablets)

This table was adapted with permission from The Regents of the University of California, RxforChange (<http://rxforchange.ucsf.edu/>).

\*Marketed by GlaxoSmithKline.

<sup>l</sup>Marketed by Pfizer.

<sup>§</sup>The USPSTF Clinical Practice Guideline<sup>37</sup> states that pregnant smokers should be encouraged to quit without medication based on insufficient evidence of effectiveness and theoretical concerns with safety. Pregnant smokers should be offered behavioral counseling interventions that exceed minimal advice to quit.

<sup>§</sup>In July 2009, the FDA mandated that the prescribing information for all products containing bupropion and varenicline include a black-box warning highlighting the risk of serious neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. Clinicians should advise patients to stop taking varenicline or bupropion SR and contact a health care provider immediately if they experience agitation, depressed mood, and any changes in behavior that are not typical of nicotine withdrawal, or if they experience suicidal thoughts or behavior. If treatment is stopped because of neuropsychiatric symptoms, patients should be monitored until the symptoms resolve.

<sup>ll</sup>Wholesale acquisition costs from Red Book Online. Thomson Reuters, July 2013.

FDA, Food and Drug Administration; MAO, monoamine oxidase; NRT, nicotine replacement therapy; OTC, over the counter (nonprescription product); Rx, prescription product.

## Tobacco Use Treatment in Patients with Psychiatric Illness

### Major Depression

Early studies showed that while patients with depression who are receiving treatment for tobacco dependence could successfully quit smoking, the incidence of depressive symptoms or a depressive episode was increased in patients who achieved cessation.<sup>51–54</sup> Until recently, many clinicians hesitated to offer tobacco use treatment to patients with major depression because of concerns that cessation would cause a depressive episode.

Current evidence shows that patients with depression should be offered tobacco use treatment since smoking may actually worsen depressive symptoms. Longitudinal studies have shown that smoking increases the risk of depressive symptoms<sup>55</sup> and the incidence of mood and anxiety disorders<sup>56</sup>; that current heavy smoking is strongly associated with current depression<sup>57</sup>; and that current smoking strongly predicts depression recurrence.<sup>58</sup> In addition, a trial of tobacco use treatment in patients with current depression showed that depressive symptoms were not worse in patients who successfully quit smoking compared with those who continued to smoke.<sup>59,60</sup> Another study showed that smokers who did not successfully quit smoking experienced a higher severity of depression symptoms compared with those who successfully quit.<sup>61</sup> A recent randomized clinical trial showed that 12 weeks of treatment with varenicline in adults ( $n = 525$ ) with past or current treated major depression doubled the odds of quitting during 52 weeks of follow-up and that no worsening of depression, anxiety, suicidal ideation, or other neuropsychiatric occurred in the varenicline or placebo groups.<sup>62</sup>

A Cochrane review<sup>63</sup> showed that use of bupropion increased long-term cessation in smokers with past depression and that adding a mood management intervention to standard tobacco use treatment further increased abstinence rates in patients with current depression.

### Anxiety Disorders and PTSD

Smoking during adolescence was associated with the onset of adulthood anxiety disorders in a large epidemiologic study.<sup>64</sup> Consistent with this finding, the prevalence of current smoking among adults with anxiety disorders is approximately 35%

to 45%, nearly double that of the general population.<sup>4</sup> Despite the bidirectional association between anxiety disorders and smoking, few clinical trials have tested tobacco use treatment in patients with anxiety disorders.<sup>28</sup>

As noted earlier, the intervention tested by McFall et al<sup>30</sup> doubled the rate of 12-month prolonged abstinence (OR, 2.26; 95% CI, 1.3–3.91) in veteran smokers with PTSD. This was achieved using a well-tolerated combination of educational and behavioral skills sessions and medications, including varenicline, bupropion, and nicotine replacement therapy.

### Bipolar Disorder and Schizophrenia

Although approximately half of patients with bipolar disorder smoke, few trials have assessed tobacco use treatment in this population.<sup>2,65</sup> Two small ( $n = 5$  for both studies) randomized controlled trials of tobacco use treatment in patients with bipolar disorder showed that bupropion<sup>66</sup> and varenicline<sup>67</sup> did not worsen psychiatric symptoms. In addition, the total number of cigarettes smoked per day was reduced in the varenicline group compared with placebo,<sup>67</sup> and patients randomized to bupropion stopped smoking.<sup>66</sup> A subsequent proof-of-concept study by Heffner et al<sup>68</sup> showed that a mood management intervention plus a nicotine patch resulted in 2 of 9 patients achieving tobacco abstinence and 7 of 9 patients achieving at least 50% reduction in daily cigarette consumption over 8 weeks. A recent large clinical trial of 203 patients with either bipolar disorder or schizophrenia showed that varenicline is efficacious for tobacco use treatment and presents no safety risks in this population.<sup>69</sup>

A Cochrane review<sup>70</sup> showed that in 7 trials, bupropion, compared with placebo, was associated with a 3-fold higher cessation rate at the end of the trials (RR, 3.03; 95% CI, 1.69–5.42), a result that endured for 6 months in 5 of the trials (RR, 2.78; 95% CI, 1.02–7.58).<sup>70</sup> Varenicline use also was associated with significantly higher cessation rates compared with placebo in 2 trials with 137 patients (RR, 4.74; 95% CI, 1.34–16.71).<sup>70</sup> Psychiatric symptoms were not worsened in patients receiving bupropion or varenicline.<sup>26,70</sup> Although individual trials have shown increased cessation rates for patients with schizophrenia who used nicotine replacement, the Cochrane review analysis did not find evidence of a significant benefit.<sup>70</sup>



## Other Considerations

Electronic cigarettes have recently received much attention, and one randomized trial suggests that use of electronic cigarettes may lead to abstinence rates similar to those seen with transdermal nicotine replacement.<sup>71</sup> However, concerns exist about the safety, regulation, content, and marketing of electronic cigarettes, including mixed evidence regarding use of e-cigarettes as a cessation aid, high levels of dual use with tobacco cigarettes, and the potential “renormalization” of smoking through advertising and public use of electronic cigarettes.<sup>72</sup>

There are several special considerations in the treatment of tobacco use in patients with psychiatric illness (Table 2). The aromatic hydrocarbons in tobacco smoke induce CYP P450 enzymes that metabolize several psychotropic medications such as clozapine, olanzapine, and haloperidol.<sup>73</sup> Thus

**Table 2. Special Considerations When Treating Smoking in Patients with Psychiatric Illness**

Consideration	Comment
Tobacco smoke–medication interactions	Tobacco smoke, but not nicotine, induces the metabolism of several psychotropic medications through the CYP1A2 enzyme. Medication doses for some psychotropic medications will need to be reduced if the patient achieves abstinence from smoking.
Nicotine withdrawal	Symptoms of nicotine withdrawal, such as irritability, sleep problems, fatigue, impaired concentration, and appetite changes, may mimic symptoms of psychiatric illness. Nicotine withdrawal can be alleviated with nicotine replacement therapy or with varenicline to some extent.
Persistence	Successful smoking cessation requires persistent efforts since most patients require more than one attempt to quit. Every attempt to quit provides opportunities for learning how to quit, and patients are more likely to succeed with each subsequent try.
Caffeine–tobacco smoke interaction	Tobacco smoke also induces the metabolism of caffeine. Smoking cessation without a reduction in caffeine intake may lead to symptoms of caffeine toxicity, including anxiety, restlessness, sleep problems, and irritability, which can mimic symptoms of psychiatric illness.

current smokers typically need higher doses of some psychotropic medications to attain therapeutic levels, and dosages should be reduced after smoking cessation to avoid potential adverse medication side effects. In addition, treating tobacco use requires persistent efforts by clinicians since most patients require more than one quit attempt to achieve abstinence, despite whether they have a psychiatric disorder.<sup>1</sup> However, every quit attempt provides opportunities for learning how to quit, and subsequent attempts are more likely to succeed.

## Case Example

A 30-year-old woman with depression and asthma presents to a primary care clinic for an annual examination. During vital sign measurement, the medical assistant asks the patient if she smokes cigarettes, and the patient answers “yes, a pack a day” and that she is “on the fence about quitting.” The primary care physician determines that the patient is currently experiencing mild depressive symptoms, evidenced by a 9-item Patient Health Questionnaire score of 8, and moderate asthma symptoms evidenced by exercise intolerance and daily cough. In addition to continuing treatment for asthma and depression, the primary care physician advises the patient to quit smoking, explaining that smoking may be associated with her chronic depressive and asthma symptoms. The physician then assesses the patient’s willingness to make a quit attempt. Despite mixed feelings about quitting, the patient states that she does want to make a quit attempt, and says that her main reason for coming to the clinic was “to get help quitting.” The physician briefly counsels the patient, encouraging her and reinforcing the message that quitting smoking is the best thing she can do for her health, prescribes varenicline with instructions and precautions, and helps her set a quit date for 1 week later. The physician then refers the patient to the state quitline for telephone support and arranges for the patient to return to the clinic in 10 days for follow-up.

## Conclusion

Tobacco dependence occurs frequently in patients with psychiatric illness, causing chronic illnesses that result in reduced life expectancy. Smoking also is associated with psychiatric symptoms in a sub-

stantial portion of patients with psychiatric illness, and although nicotine withdrawal syndrome may mimic psychiatric symptoms, withdrawal can be alleviated by behavioral and pharmacological modalities. Effective tobacco dependence treatments are available for patients with psychiatric illness. Reframing tobacco use treatment as a way to reduce overall psychiatric symptom burden and improve the general health of patients with psychiatric illness may help clinicians make tobacco use treatment a higher priority in the care of patients with psychiatric illness.

## References

1. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine Tob Res* 2008;10:1691–715.
2. Dickerson F, Stallings CR, Origonia AE, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011. *Psychiatr Serv* 2013;64:44–50.
3. LeCook B, Wayne GF, Kafali N, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. *JAMA* 2014;311:172–82.
4. Lasser K, Boyd W, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. *JAMA* 2000;284:2606–10.
5. Schroeder SA, Morris CD. Confronting a neglected epidemic: tobacco cessation for persons with mental illnesses and substance abuse problems. *Annu Rev Public Health* 2010;31:297–314.
6. Centers for Disease Control and Prevention (CDC). Vital Signs: current cigarette smoking among adults aged  $\geq 18$  years with mental illness—United States, 2009–2011. *MMWR Morb Mortal Wkly Rep* 2013; 62:81–7.
7. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res* 2005;80:45–53.
8. Himelhoch S, Lehman A, Kreyenbuhl J, et al. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. *Am J Psychiatry* 2004;161:2317–9.
9. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. *Biol Psychiatry* 2003;54: 216–26.
10. Roshabaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. *Psychiatr Serv* 2009;60:174–6.
11. Druss BD, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. *Med Care* 2011; 49:599–604.
12. Schroeder SA. A 51-year-old woman with bipolar disorder who wants to quit smoking. *JAMA* 2009; 301:522–31.
13. Daumit GL, Pratt LA, Crum RM, Powe NR, Ford DE. Characteristics of primary care visits for individuals with severe mental illness in a national sample. *Gen Hosp Psychiatry* 2002;24:391–5.
14. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve month use of mental health services in the United States: results from the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62:629–40.
15. McAfee T. Encouraging smokers to talk with their physicians about quitting. *JAMA* 2013;309:2329–30.
16. Fiore MC, McCarthy DE, Jackson TC, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. *Prev Med* 2004; 38:412–20.
17. Prochaska JJ. Smoking and mental illness—breaking the link. *N Engl J Med* 2011;365:196–8.
18. Cerimele JM, Katon W. Associations between health risk behaviors and symptoms of schizophrenia and bipolar disorder: a systematic review. *Gen Hosp Psychiatry* 2013;35:16–22.
19. Ostacher MJ, LeBeau RT, Perlis RH, et al. Cigarette smoking is associated with suicidality in bipolar patients. *Bipolar Disord* 2009;11:766–71.
20. Kotov R, Guey LT, Bromet EJ, Schwartz JE. Smoking severity in schizophrenia: diagnostic specificity, symptom correlates and illness severity. *Schizophr Bull* 2010;36:173–81.
21. Dodd S, Brnabic AJM, Fitzgerald PB, et al. A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder. *Compr Psychiatry* 2010;51:504–9.
22. Heffner JL, Delbello MP, Anthenelli RM, et al. Cigarette smoking and its relationship to mood disorder symptoms and co-occurring alcohol and cannabis use disorders following first hospitalization for bipolar disorder. *Bipolar Disord* 2012;14:99–108.
23. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. *Am J Psychiatry* 2010;167:668–75.
24. Prochaska JJ, Reyes RS, Schroeder SA, Daniels AS, Doederlein A, Bergeson B. An online survey of tobacco use, intentions to quit, and cessation strategies among people living with bipolar disorder. *Bipolar Disord* 2011;13:466–73.
25. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? *Addiction* 2010;105: 1176–89.

26. Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. *J Clin Psychiatry* 2012;73:e1039–47.
27. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. *Psychiatr Serv* 2002;53:1166–70.
28. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. *Annu Rev Clin Psychol* 2009;5:409–31.
29. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. *J Consult Clin Psychol* 2003;71:657–63.
30. McFall M, Saxon AJ, Malte CA, et al. Integrating tobacco cessation into mental health care for post-traumatic stress disorder: a randomized controlled trial. *JAMA* 2010;304:2485–93.
31. Piper ME, Rodock M, Cook JW, Schlam TR, Fiore MC, Baker TB. Psychiatric diagnoses among quitters versus continuing smokers 3 years after their quit day. *Drug Alcohol Depend* 2013;128:148–54.
32. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. *Br J Psychiatry* 2003;183:534–9.
33. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services; 2008.
34. Fiore MC, Baker TB. Treating smokers in the health care setting. *N Engl J Med* 2011;365:1222–31.
35. Rigotti NA. Strategies to help a smoker who is struggling to quit. *JAMA* 2012;308:1573–80.
36. Benowitz NL. Nicotine addiction. *N Engl J Med* 2010;362:2295–303.
37. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. *Nicotine Tob Res* 2007;9:315–27.
38. Smith PH, Homish GG, Giovino GA, Kozlowski LT. Cigarette smoking and mental illness: a study of nicotine withdrawal. *Am J Public Health* 2013;104:e127–33.
39. Hughes JR, Gust SW, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal: a replication and extension. *Arch Gen Psychiatry* 1991;48:52–9.
40. Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. *Mayo Clin Proc* 1995;70:209–13.
41. Quinn V, Hollis JF, Smith KS, et al. Effectiveness of the 5-As tobacco cessation treatments in nine HMOs. *J Gen Intern Med* 2008;24:149–54.
42. Centers for Disease Control and Prevention (CDC). Quitting smoking among adults—United States, 2001–2010. *MMWR Morb Mort Wkly Rep* 2011;60:1513–9.
43. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. *Cochrane Database Syst Rev* 2010;1:CD006936.
44. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Int Med* 2009;169:2148–55.
45. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry* 2009;66:1253–62.
46. Ebbert JJO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA* 2014;311:155–63.
47. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. *Am J Psychiatry* 2013;170:1460–7.
48. Smokefree.gov [homepage on the Internet]. Washington, DC: U.S. Department of Health and Human Services; 2013. Available from: [www.smokefree.gov](http://www.smokefree.gov). Accessed August 1, 2013.
49. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. *N Engl J Med* 2002;347:1087–93.
50. Hebert KK, Cummins SE, Hernandez S, Tedeschi GJ, Zhu SH. Current major depression among smokers using a state quitline. *Am J Prev Med* 2011;40:47–53.
51. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. *JAMA* 1990;264:1546–9.
52. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. *Am J Psychiatry* 1997;154:263–5.
53. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. *Lancet* 2001;357:1929–32.
54. Hughes JR. Depression during tobacco abstinence. *Nicotine Tob Res* 2006;9:443–6.
55. Boden JM, Fergusson DM, Horwood LJ. Cigarette smoking and depression: tests of causal linkages using a longitudinal birth cohort. *Br J Psychiatry* 2010;196:440–6.
56. Mojtabai R, Crum RM. Cigarette smoking and onset of mood and anxiety disorders. *Am J Pub Health* 2013;103:1656–65.
57. Khaled SM, Bulloch AG, Williams JVS, Hill JC, Lavorato DH, Patten SB. Persistent heavy smoking as risk factor for major depression (MD) incidence—evidence from a longitudinal Canadian cohort of the National Population Health Survey. *J Psychiatr Res* 2012;46:436–43.
58. Colman I, Naicker K, Zeng Y, Ataullahjan A, Sentihselvan A, Patten SB. Predictors of long-term prognosis of depression. *CMAJ* 2011;183:1969–76.
59. Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health

- outpatients: a randomized clinical trial. *Am J Pub Health* 2006;96:1808–14.
60. Prochaska JJ, Hall SM, Tsoh JY, et al. Treating tobacco dependence in clinically depressed smokers: effects of smoking cessation on mental health functioning. *Am J Pub Health* 2008;98:446–8.
61. Berlin I, Chen H, Covey LS. Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day. *Addiction* 2010;105:2209–16.
62. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression. *Ann Intern Med* 2013;159:390–400.
63. van der Meer R, Willemsen MC, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. *Cochrane Database Syst Rev* 2013;8:CD006102.
64. Johnson JG, Cohen P, Pine DS, Klein DF, Kasen S, Brook JS. Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. *JAMA* 2000;284:2348–51.
65. George TP, Wu BS, Weinberger AH. A review of smoking cessation in bipolar disorder: implications for future research. *J Dual Diagn* 2012;8:126–30.
66. Weinberger AH, Vessicchio JC, Sacco KA, Creedon CL, Chengappa KN, George TP. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. *J Clin Psychopharmacol* 2008;28:584–7.
67. Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. *J Dual Diagn* 2012;8:131–2.
68. Heffner JL, Anthenelli RM, DelBello MP, Stahl L, Strakowski SM. Mood management and nicotine patch for smoking cessation in adults with bipolar disorder. *Nicotine Tob Res* 2013;15:1805–6.
69. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *JAMA* 2014;311:145–54.
70. Tsoi DT, Porwall M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. *Cochrane Database Syst Rev* 2013;2:CD007253.
71. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet* 2013;382:1629–37.
72. Fairchild AL, Bayer R, Colgrove J. The renormalization of smoking? E-cigarettes and the tobacco “endgame”. *N Engl J Med* 2013;370:293–5.
73. Zevin S, Benowitz NL. Drug interactions with tobacco smoke: an update. *Clin Pharmacokinet* 1999;36:425–38.